Friday, 17 September 2021 | 06:46 WIB

UK Collaborates with CureVac to Develop New COVID-19 Variant Vaccine

UK Collaborates with CureVac to Develop New COVID-19 Variant Vaccine (special)

LONDON, NETRALNEWS.COM - The British Government has agreed to collaborate with Germany-based biotechnology company CureVac. The collaboration is aimed at developing a vaccine to fight against the new variant of COVID-19, and to target the early order for 50 million doses if needed.

British Prime Minister Boris Johnson has quoted the possibility of the new variant of COVID-19 as one of the biggest reason to launch the vaccine, and hopes that the economy can be opened again after the lockdowns by spring.

The government said the Pfizer/BioNTech and Oxford/AstraZeneca vaccine seem to work well on the new variant which dominates United Kingdom now.

However, we have to be ready to face all possibilities and to improve the United Kingdom manufacturing capacity so that the vaccine can be developed by using the famous genomics expertise to fight against the new variant," said UK Minister of Health Matt Hancock on Friday (02/05/2021).

The British government declared that almost all vaccines, which are developed through the institute, are the new kind of the CureVac injections which recently went through the last stage of clinical test.

For CureVac, the alliance finds another way to catch up with the famous mRNA developer (BioNTech and Moderna) and to get the front position back for the new vaccine generation that prevents more than one variant in a treatment.

On Wednesday (02/03), CureVac announced their partnership with GlaxoSmithKline from Britain to develop the vaccine.

CureVac said the reason why they chose United Kingdom was their main role in analysing the virus genetic order when the pathogen grows and the country leader  starts launching the first vaccine generation.

"The United Kingdom government and its Vaccine Task Force are in the front-line of monitoring, vaccine development, and vaccine delivery during this pandemic," said CureVac Business and Commercial Officers Chief Dr. Antony Blanc.